Clinical trial
Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon…
NCT00390897 · PETHEMA Foundation, Other · Completed
Key facts
| NCT number | NCT00390897 |
|---|---|
| Title | Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia |
| Official title | Randomised Multicentre Phase IV Study to Compare Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec® in Combination With Interferon Alpha at Low Doses in the Treatment of Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukaemia |
| Lead sponsor | PETHEMA Foundation, Other |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Chronic Myeloid Leukaemia |
| Intervention type | Drug |
| Interventions | Glivec, Interferon |
| Enrollment | 360 |
| Start date | Jul 1, 2003 |
| Primary completion | Oct 1, 2006 |
| Completion | Dec 1, 2007 |
| First posted | Oct 23, 2006 |
| Last update posted | Nov 27, 2008 |
| Countries | Spain |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: